Beijing Luzhu Biotechnology Completes U.S. Phase 1 Trial of LZ901, Demonstrating Strong Safety and Immunogenicity
Beijing Luzhu Biotechnology Co., Ltd. (HKG: 2480) announced today that its Phase 1 clinical trial of...
Clinical trial results
CMS Announces Phase 3 Success of Ruxolitinib Cream in Atopic Dermatitis
China Medical System Holdings Limited (CMS, HKG: 0867) reported that its Phase 3, randomized, double‑blind, placebo‑controlled...
Roche’s giredestrant Yields Positive PFS Results in evERA Phase III Study
Roche (SWX: ROG, OTCMKTS: RHHBY) announced that its Phase III evERA trial has met both co‑primary...
Eli Lilly’s Orforglipron Outperforms Oral Semaglutide in ACHIEVE‑3 Phase 3 Trial
Eli Lilly and Company (NYSE: LLY) announced positive topline results from the open‑label, randomized Phase 3...
Ascletis Pharma Reports 28‑Day ASC30 Study Results at EASD
Ascletis Pharma Inc. (HKG: 1672) announced that its Phase Ib multiple‑ascending‑dose (MAD) study of the oral...
BioNTech and BMS Reveal Promising Interim Results for Pumitamig in ES‑SCLC
BioNTech SE (NASDAQ: BNTX) and Bristol-Myers Squibb (BMS, NYSE: BMY) disclosed interim data from a...
Summit Therapeutics Presents 2025 HARMONi Study Results at World Lung Cancer Conference
Summit Therapeutics (NASDAQ: SMMT) disclosed longer‑term progression‑free survival (PFS) data from its HARMONi trial of...
Duality Biotherapeutics Hits PFS Milestone with DB‑1303/BNT323 in HER2‑Positive Breast Cancer
China‑based Duality Biotherapeutics, Inc. (HKG: 9606) announced that its Phase III study of the HER2‑targeting antibody‑drug...
Innovent Biologics Announces Strong Phase II Results for Tigulixostat in Chinese Gout Patients
China-based Innovent Biologics Inc. (HKG: 1801) revealed that its next‑generation xanthine oxidase inhibitor (XOI), tigulixostat...
Junshi Biosciences’ JS005 IL‑17A Antibody Shows Promise in Phase III Psoriasis Trial
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced that its proprietary recombinant humanized...
MSD Reports Positive Phase 3 CORALreef Lipids Results for Oral PCSK9 Inhibitor Enlicitide
US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) disclosed encouraging topline results from the...
Novo Nordisk’s STEER Study: Wegovy Cuts Cardiovascular Risk 57 % vs. Tirzepatide
Danish biopharmaceutical giant Novo Nordisk A/S (NYSE: NVO) presented compelling real‑world evidence from the STEER...
RemeGen’s Telitacicept Hits Primary Endpoint in Phase III IgA Nephropathy Trial
China‑based RemeGen Co., Ltd. (HKG: 9995, SHA: 688331) on Aug, 27, 2025announced that its first‑in‑class BLyS/APRIL...
Regeneron’s Cemdisiran Beats Key Milestones in Phase III gMG Trial
US-based Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) on Aug 27, 2025 disclosed that its investigational monotherapy, cemdisiran,...
Zhifei Biological’s Adult and Adolescent DTaP Vaccine Gains NMPA Trial Approval
Chongqing Zhifei Biological Co., Ltd. (SHE: 300122), based in China, announced that its Acellular Pertussis,...
Novartis’ Ianalumab Shows Positive Results in Phase 3 Trials for ITP and Sjögren’s Disease
Swiss pharmaceutical giant Novartis (NYSE: NVS) announced positive top-line results from the Phase 3 VAYHIT2...
RemeGen Announces Positive Phase III Results for Telitacicept in Primary Sjögren’s Syndrome
China-based RemeGen Co., Ltd. (SHA: 688331, HKG: 9995), a China-based pharmaceutical firm, announced on August...
TYK Medicines’ Asandeutertinib Shows Promising Results in Phase II Trial for EGFR-Mutated NSCLC
China-based TYK Medicines, Inc. (HKG: 2410) announced on August 14, 2025, that the results of...
Eli Lilly Reports Strong Q2 Growth but Shares Dip on Orforglipron Data
US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) reported another strong quarterly performance with...
Eli Lilly’s Jaypirca Achieves Primary Endpoint in Phase III BRUIN CLL-314 Trial
US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) announced on July 29, 2025, that...